BR112013000867A2 - composto de purina seletivos para delta p110 de pi3k e métodos de uso. - Google Patents

composto de purina seletivos para delta p110 de pi3k e métodos de uso.

Info

Publication number
BR112013000867A2
BR112013000867A2 BR112013000867A BR112013000867A BR112013000867A2 BR 112013000867 A2 BR112013000867 A2 BR 112013000867A2 BR 112013000867 A BR112013000867 A BR 112013000867A BR 112013000867 A BR112013000867 A BR 112013000867A BR 112013000867 A2 BR112013000867 A2 BR 112013000867A2
Authority
BR
Brazil
Prior art keywords
delta
pi3k
methods
purine compound
compounds
Prior art date
Application number
BR112013000867A
Other languages
English (en)
Inventor
Brian Safina
Daniel P Sutherlin
Jun Li
Zachary Sweeney
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112013000867A2 publication Critical patent/BR112013000867A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composto de purina seletivos para delta p110 de pi3k e métodos de uso. a invenção provê compostos que tem a fórmula geral: e estereoisômeros, tautômeros ou sai aceitos farmaceuticamente desses, em que r^1^,r^2^,r^3^,r^4^ e n são definidos aqui, composições incluindo os compostos e método de utilizar os compostos para tratar uma doença ou distúrbio mediado pelo isoforma delta de p110 de quinase pi3 selecionado de distúrbios imunológicos, câncer, doenças cardiovasculares, infecção viral, inflamação,distúrbios de funções de metabolismo/endócrinas e distúrbios neurológicos.
BR112013000867A 2010-07-14 2011-07-13 composto de purina seletivos para delta p110 de pi3k e métodos de uso. BR112013000867A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36432410P 2010-07-14 2010-07-14
PCT/EP2011/061930 WO2012007493A1 (en) 2010-07-14 2011-07-13 Purine compounds selective for ρi3κ p110 delta, and methods of use

Publications (1)

Publication Number Publication Date
BR112013000867A2 true BR112013000867A2 (pt) 2016-05-17

Family

ID=44532789

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013000867A BR112013000867A2 (pt) 2010-07-14 2011-07-13 composto de purina seletivos para delta p110 de pi3k e métodos de uso.

Country Status (11)

Country Link
US (1) US8293736B2 (pt)
EP (1) EP2593455B1 (pt)
JP (1) JP5555378B2 (pt)
KR (1) KR101531117B1 (pt)
CN (1) CN103003279B (pt)
BR (1) BR112013000867A2 (pt)
CA (1) CA2802808A1 (pt)
ES (1) ES2536780T3 (pt)
MX (1) MX2013000389A (pt)
RU (1) RU2013104038A (pt)
WO (1) WO2012007493A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009146406A1 (en) * 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
CN102711766B (zh) * 2009-11-12 2014-06-04 霍夫曼-拉罗奇有限公司 N-9-取代的嘌呤化合物、组合物和使用方法
SG190890A1 (en) 2010-12-16 2013-07-31 Hoffmann La Roche Tricyclic pi3k inhibitor compounds and methods of use
EP2790705B1 (en) 2011-12-15 2017-12-06 Novartis AG Use of inhibitors of the activity or function of pi3k
EA035391B1 (ru) 2012-11-08 2020-06-05 Ризен Фармасьютикалз Са Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы
CN104513254B (zh) 2013-09-30 2019-07-26 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
MX2016004964A (es) 2013-10-16 2016-07-11 Shanghai Yingli Pharm Co Ltd Compuesto heterociclico fusionado, metodo de preparacion del mismo, composicion farmaceutica, y usos del mismo.
WO2015188369A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
EP3209664B1 (en) 2014-10-22 2020-06-03 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
ES2749679T3 (es) 2014-10-22 2020-03-23 Bristol Myers Squibb Co Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k
MX2017012390A (es) 2015-03-30 2018-01-26 Daiichi Sankyo Co Ltd Derivados de 6-morfolinil-2-pirazolil-9h-purina y su uso como inhibidores de fosfoinositol-3-cinasa (pi3k).
GB201514751D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
WO2018062382A1 (ja) * 2016-09-29 2018-04-05 第一三共株式会社 [2-(1-メチル-1h-ピラゾール-4-イル)-6-(モルホリン-4-イル)-9h-プリン-8-イル][4-(モルホリン-4-イル)ピペリジン-1-イル]メタノン及びその製薬上許容される塩の結晶
ES2911522T3 (es) 2016-12-02 2022-05-19 Daiichi Sankyo Co Ltd Novedosa endo-ß-n-acetilglucosaminidasa
JP7358890B2 (ja) 2019-10-01 2023-10-11 富士フイルムビジネスイノベーション株式会社 物体質感計測装置

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3016378A (en) 1959-07-01 1962-01-09 Thomae Gmbh Dr K Amino-substituted purine derivatives
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS60260579A (ja) 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4782137A (en) 1984-01-24 1988-11-01 Immunex Corporation Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same
DE3406533A1 (de) 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
ES2360933T3 (es) 2000-04-27 2011-06-10 Astellas Pharma Inc. Derivados de heteroarilo condensados.
EP1427413A2 (en) 2001-09-13 2004-06-16 Synta Pharmaceuticals Corporation 2-aroylimidazole compounds for treating cancer
JP2005512972A (ja) 2001-10-12 2005-05-12 アイアールエム エルエルシー キナーゼ阻害剤足場およびそれらの調製方法
US6949644B2 (en) 2001-10-12 2005-09-27 Irm Llc Methods for the synthesis of substituted purines
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US20050288503A1 (en) 2002-09-06 2005-12-29 Adams Jerry L Novel compounds
AU2003284142A1 (en) 2002-10-15 2004-05-04 Synta Pharmaceuticals Corp Aromatic bicyclic heterocyles to modulate 1L-12 production
EP1626725A4 (en) 2003-05-29 2006-06-14 Synta Pharmaceuticals Corp Heterocyclic compounds for the prevention and treatment of disorders associated with excessive bone formation
HUE030950T2 (en) 2004-05-13 2017-06-28 Icos Corp Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP1934174B1 (en) 2005-10-07 2011-04-06 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
JP5546240B2 (ja) 2006-04-26 2014-07-09 ジェネンテック, インコーポレイテッド 医薬化合物
KR101402474B1 (ko) 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
DK2024372T3 (da) 2006-04-26 2010-09-20 Hoffmann La Roche Thieno[3,2-d]pyrimidin-derivat, der er egnet som P13K inhibitor
CL2007002866A1 (es) 2006-10-04 2008-07-04 Pharmacopeia Inc Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
MY180595A (en) 2006-12-07 2020-12-03 Genentech Inc Phosphoinositide 3-kinase inhibitor compounds and methods of use
MX2009005925A (es) 2006-12-07 2009-08-12 Genentech Inc Compuestos inhibidores de fosfoinositida 3-quinasa y los metodos de uso.
US20080233127A1 (en) 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
WO2008116909A1 (en) 2007-03-28 2008-10-02 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
US7893060B2 (en) * 2007-06-12 2011-02-22 F. Hoffmann-La Roche Ag Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
EP2207781B1 (en) 2007-09-24 2012-11-28 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
US20110009403A1 (en) * 2007-10-05 2011-01-13 S*Bio Pte Ltd. 2-morpholinylpurines as inhibitors of pi3k
JP5638955B2 (ja) 2007-10-26 2014-12-10 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Pi3キナーゼ阻害剤として有用なプリン誘導体
JP5608099B2 (ja) * 2008-01-30 2014-10-15 ジェネンテック, インコーポレイテッド ピラゾロピリミジンpi3k阻害剤化合物および使用方法
WO2009146406A1 (en) 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
CA2730271A1 (en) * 2008-07-07 2010-01-14 Xcovery Holding Company Llc Pi3k isoform selective inhibitors
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
EP2411387B1 (en) * 2009-03-27 2015-08-19 VetDC, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
CN102459272B (zh) * 2009-05-27 2014-08-06 健泰科生物技术公司 对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法
EP2451802A1 (en) * 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy

Also Published As

Publication number Publication date
JP2013531022A (ja) 2013-08-01
MX2013000389A (es) 2013-03-08
KR20130038921A (ko) 2013-04-18
WO2012007493A1 (en) 2012-01-19
ES2536780T3 (es) 2015-05-28
RU2013104038A (ru) 2014-08-20
CA2802808A1 (en) 2012-01-19
JP5555378B2 (ja) 2014-07-23
EP2593455A1 (en) 2013-05-22
CN103003279B (zh) 2015-09-23
CN103003279A (zh) 2013-03-27
EP2593455B1 (en) 2015-03-18
US20120015931A1 (en) 2012-01-19
US8293736B2 (en) 2012-10-23
KR101531117B1 (ko) 2015-06-23

Similar Documents

Publication Publication Date Title
BR112013000867A2 (pt) composto de purina seletivos para delta p110 de pi3k e métodos de uso.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MX340013B (es) Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso.
MX2009010881A (es) Compuestos farmaceuticos.
IL201365A0 (en) Pyrimidine derivatives as inhibitors of phosphatidylinositol - 3 kinase
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
NO20084931L (no) Farmasoytiske sammensetninger
MX2009002171A (es) Derivados de triazol como inhibidores de cinasas.
MX2013004298A (es) Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa.
NZ612909A (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
EA201590624A1 (ru) Циклические эфиры пиразол-4-ил-гетероциклил-карбоксамидных соединений и способы их применения
MX2011012520A (es) Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos.
WO2009132202A3 (en) Macrocyclic compounds and their use as kinase inhibitors
MX2010004705A (es) Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7.
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2008060621A3 (en) Aminopyrrolidines as chemokine receptor antagonists
MX2010005700A (es) Amino triazoles como inhibidores pi3k.
BR112015026721A2 (pt) derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1h-pirrolo[2,3-c]piridina como inibidores de nik para o tratamento de câncer
WO2013038429A3 (en) Novel sglt inhibitors
WO2012101654A3 (en) Novel triazine compounds
NO20085257L (no) Purinonderivater som HM74a-agonister
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
MX2009009154A (es) Derivados de espiro-pirano-pirazol.
WO2014106800A3 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]